GLP1R and atherosclerosis: Utilize GLP-1 receptor agonists in individuals diagnosed with T2DM and either established atherosclerotic cardiovascular disease (ASCVD) or at a heightened risk for ASCVD to mitigate the likelihood of myocardial infarction, stroke, or cardiovascular death, irrespective of A1C levels and other therapies targeting glucose or cardiovascular health.